gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · CLYMHealthcarePharmaceuticals

Climb Bio, Inc. Common Stock (CLYM)

$9.33−4.31%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$9.75▲ 387.50% in range
Nov 3, 2025Low $1.64 · High $17.84Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Climb Bio closed at $9.33 on Nov 4, down 4.31%, 47.7% below its 52-week closing high. Volume of 1.0M shares was 0.90× its 20-day average (close to normal).

Split-adjusted performance: -12.6% over one month, -23.6% over six months, +366.5% over one year.

Short interest was 9.8M shares at the Oct 15 settlement (25.6% of float, 10.3 days to cover).

Market cap$535.9M57.4M shares
Revenue · quarter$0.00—
Diluted EPS$-0.18—
P/E · TTM—
Net margin—
Dividend yieldNone
52-week range1.64 – 17.84−47.7% from high
Volume1.0M0.90× 20-day avg
Volatility · 60d80.8%Annualised
Short % of float25.6%10.3 days to cover
Net cash$183.1MCash $183.1M
Next earnings—Not scheduled
Split-adjusted performance
1W −7.8%1M −12.6%3M −33.4%6M −23.6%YTD +133.3%1Y +366.5%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum52
Revenue growth—
Net margin—
Value (low P/E)—
Size62

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short9.8M+0.7% vs prior
Days to cover10.3Settled Oct 15
% of float25.6%
Short vol. 10d56.5%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CLYMClimb Bio$9.33−4.31%−23.6%———$535.9M
OVIDOvid Therapeutics$2.74+14.17%−1.4%−88.3%−2047.6%—$535.1MCompare
PBYIPUMA BIOTECHNOLOGY$10.69+4.60%+43.5%+7.8%14.5%20.7$551.8MCompare
NGNENeurogene$27.58+3.41%−14.7%———$551.9MCompare
CAPRCapricor Therapeutics$8.92+8.25%−74.1%———$518.6MCompare
STTKShattuck Labs$5.15−5.85%−22.9%———$516.9MCompare
FTHFaeth Therapeutics$19.99+1.73%————$516.6MCompare
CBIOCrescent Biopharma$13.82+5.82%−23.5%———$513.4MCompare
CTMXCytomX Therapeutics$2.35+7.80%−43.1%−92.4%−1457.4%—$512.1MCompare

News about Climb Bio

All news →
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026GlobeNewswire Inc. · Oct 24, 2026▲ Positive

Quick answers

What does Climb Bio do?
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
What is CLYM's market cap?
$535.88M, based on the Nov 4 close of $9.33.
Does Climb Bio pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CLYM is sold short?
9.8M shares, 25.6% of float, as of Oct 15, 2026.
What sector is CLYM in?
Healthcare, in the Pharmaceuticals industry.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.

HQ: Wellesley Hills, MA29 employeesListed Aug 10, 2021climbbio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology